Plain-English translation of NCT06906926 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Harmony TPV, a new heart valve that can be implanted without open-heart surgery to treat severe pulmonary valve regurgitation — a condition where the pulmonary valve (which sits between your heart's right ventricle and lungs) doesn't close properly and allows blood to leak backward. The study will follow 80 patients across multiple centers in Europe to see how well this treatment works and how safe it is in real-world practice.
People with severe pulmonary valve regurgitation often need surgery to fix or replace the valve, but surgery carries risks. This medication offers a less invasive option that can be placed through a catheter (thin tube) instead of requiring open-heart surgery, potentially reducing recovery time and complications.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the Harmony TPV implant as part of standard care at a participating heart center. The implant procedure uses a catheter (a thin tube) threaded through your blood vessels to place the valve — avoiding the need for open-heart surgery. After the procedure, you will attend follow-up appointments at scheduled intervals so the research team can monitor how well the valve is working and check for any complications.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Denmark
France
Germany